A Comparison of the Effect of Olmesartan Medoxomil, Losartan Potassium, and Atenolol on the Ability of Overweight Patients With High Blood Pressure to Respond to Insulin

Inclusion criteria

• Patients between the ages of 18 and 75 years (inclusive)
• Willingness to undergo insulin clamp procedure twice
• Overweight or obese (BMI=25-39 kg/m2)
• Subject must meet one of the following two blood pressure criteria at week-2 and at week-1: Systolic blood pressure 140-179 mmHg and diastolic blood pressure 85-99 mmHg OR Systolic blood pressure < 140 mmHg and diastolic blood pressure 90-99 mmHg
• If female, must have negative serum pregnancy test at screening and be either post-menopausal, had a hysterectomy or tubal ligation at least 6 months before consent or if of childbearing potential, must practice approved measures of birth control throughout study

Exclusion criteria

• Systolic blood pressure > 179 mmHg
• Diastolic blood pressure > 99 mmHg or < 85 mmHg
• Diagnosis of diabetes mellitus
• History of myocardial infraction, percutaneous transluminal coronary revascularization, coronary artery bypass graft, unstable angina pectoris or an episode of heart failure requiring hospitalization
• Previous history of a cerebrovascular accident or a transient ischemic attack
• History of allergic response to atenolol, losartan potassium, olmesartan medoxomil or any of their components
• Any serious disorder, including pulmonary, hepatic, renal, gastrointestinal (including clinically significant malabsorption), uncontrolled endocrine/metabolic, hematologic/oncologic (within the last 5 years), neurologic, and psychiatric diseases, that would interfere with the conduct of the study or interpretation of the data
• Laboratory abnormalities that could compromise subject safety